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ABSTRACT 
Objective: Levetiracetam (LEV) is an anti-epileptic drug, initially approved as an adjunct therapy in adult patients with partial-onset seizures, and 
used as monotherapy treatment during pregnancy. However, very few, if none, investigations have been focused on LEV neurotoxicity or 
hepatotoxicity at the molecular level. This study aimed to evaluate the genotoxic and mutagenic potential of LEV, in liver and brain tissues of treated 
pregnant rats and their fetuses during pregnancy. 
Methods: LEV was administered to pregnant female albino rats at doses 300 and 600 mg/kg b. w, from gestation days 5-18. Comet assay, DNA 
fragmentation were performed for detection of DNA damage. Single-stranded conformation polymorphism (SSCP) followed by DNA sequencing 
were accomplished for detecting possible mutagenicity.  
Results: Administration of the two tested doses of LEV resulted in a significant increase of DNA damage as detected by alkaline Comet assay, and an 
appearance of both apoptotic laddered and smeared DNA in the tissues tested. Moreover, a significant incidence of mutations in exon 2 and 3 of 
Harvey rat sarcoma viral oncogene (HRAS) gene, were detected in fetal liver and brain tissues respectively, using single-stranded conformation 
polymorphism (SSCP) and were confirmed by DNA sequencing. 
Conclusion: Maternal and fetal DNA damage induced by LEV was evidenced in our study, even at the commonly used therapeutic dose (300 mg/kg), 
and thus these side effects should be considered when using LEV for long-term during pregnancy.  
Keywords: Mutagenicity, SSCP, HRAS gene mutation, Comet assay, Levetiracetam. 
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INTRODUCTION 
Epilepsy is considered as the second common chronic neurological 
disorder and one of the most important neurological syndromes 
during pregnancy. It's marked by sudden recurrent episodes of 
sensory, motor or autonomic disturbance, with or without loss of 
consciousness or convulsions, associated with brain abnormal 
electrical activity [1]. Antiepileptic drugs (AEDs) are used to prevent 
epileptic seizures. Despite the high risk of treating a pregnant 
woman suffering from epilepsy with AED, due to the more frequent 
occurrence of complications, it may be dangerous to stop or even 
change the AED regimen during pregnancy due to the frequency and 
severity of their underlying epileptic disorder. Thus, prescribing 
AEDs in pregnancy is a challenge to clinicians. 
Levetiracetam (Keppra) is an anti-epileptic drug, initially approved 
as an adjunct treatment for patients with refractory partial seizures, 
and is now used as monotherapy in pregnancy [2, 3]. It’s mechanism 
of action implicates blocking N-type calcium channels and indirectly 
inducing the major inhibitory neurotransmitters GABA and glycine 
resulting in the blunting of excessive neuronal activity in the brain 
[4]. As apoptosis is regulated by growth factors and cytokines as 
well as by neurotransmitters [5], any compound that interferes with 
these processes may trigger apoptotic death of neurons [6]. 
Simultaneously, there have been two case reports of hepatic failure 
secondary to treatment with LEV [7, 8]. Additionally, a reduction in 
LEV dose by 50% is recommended in patients with severe liver 
cirrhosis (Child-Pugh Class C), suffering from seizure prophylaxis, 
due to the drop in the total clearance of the drug by 57% [9]. 
However, to our knowledge, there is no information concerning the 
neurotoxicity or hepatotoxicity of LEV at the molecular level. 
The majority of antiepileptic drugs are trans-placental xenobiotic 
[10]. Moreover, The developing fetuses of pregnant women with 
epilepsy, who are treated with AEDs, might be associated with 
increased risk of major congenital malformations (MCM), post-natal 
developmental anomalies, developmental delay, fetal death and 
adverse pregnancy outcomes [11]. This has drawn the attention to 
the possible genotoxicity or/and mutagenicity of LEV in treated 
mothers and their fetuses. 
Therefore, the present study was undertaken to determine the 
potential genotoxic and mutagenic effects of LEV in liver and brain 
cells of treated pregnant rats and their fetuses during pregnancy. 
Alkaline Comet and DNA fragmentation assays were conducted to 
evaluate Levetiracetam DNA damage. The other two test systems 
specified mutations in exons 2 and 3 of HRAS gene, as an example of 
an oncogene using PCR-SSCP, followed by sequencing of the mutant 
and normal PCR products. Oncogenes are the mutant forms of proto-
oncogenes that regulate the cell proliferation such as (RAS, RET, KIT, 
MET). Mutations of hot-spots codons of exon 2 or/and exon 3 in 
HRAS genes may implicate in the development of benign and 
malignant tumors [12] or Costello syndrome disease in children 
[13]. Thus, mutagenicity studies that measure these types of 
mutations can shed some light on the risk assessment of LEV under 
sub-chronic administration. 
MATERIALS AND METHODS 
Chemicals 
Levetiracetam (LEV) was purchased from UCB Pharmaceutical 
Sector (Chemin du Foriest, Belgium). All other chemicals were of 
analytical grade and were purchased from Sigma-Aldrich (St. Louis, 
MO). 
Animals 
Female albino rat (Rattus Norvegicus) were obtained from the 
animal house of Theodor-Bilharz Research Institute, (Giza, Egypt). 
All procedures involving rats followed the specifications 
recommended in The Guide for the Care and Use of Laboratory 
Animals [14]. Animals were housed (5/cage), the temperature in the 
experimental animal room was about 24 °C and relative humidity 
about 60%. The light cycle was 12 h light/12 h dark. Animals were 
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allowed free access to tap water and certified laboratory rodent 
chow. The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC), Faculty of Science, Cairo University, 
Egypt (CUFS/S/phy/14/14).  
Experimental design 
Fifteen Females of 11-13 w old (275±24 g body weight (b. w)) were 
selected for the present study, and vaginal smears were prepared 
every morning and examined under the light microscope according 
to the method of Snell [15] for 5 d to select the rat in the proestrus.  
Each two females with regular estrus cycle were selected in the 
proestrus stage and caged together with one male overnight under 
controlled environmental conditions of temperature, humidity and 
light. The first day of gestation was determined by the presence of 
sperms in the vaginal smear [16]. The pregnant rats were then 
randomly allocated into three groups of five each. LEV was 
administrated intragastrically daily, from the 5th day to the 18thday 
of gestation at 9:00 a. m (±30 min) to treatment groups; Group A 
received 300 mg/kg (equivalent low therapeutic dose) while Group 
B received 600 mg/kg (equivalent greater therapeutic dose) of LEV. 
Group C (the control group) received distilled water by intragastric 
route. The present study was done in healthy (non-epileptic) 
pregnant rats. The rats were weighed daily, and the doses of LEV 
were adjusted according to their bodyweight. On the 18th day of 
gestation, all pregnant rats of groups (A, B, and C) were euthanized 
under chloroform vapor and sacrificed by decapitation after being 
fasted overnight. Fetuses recovered through caesarian section were 
removed from their membranes and were separated from their 
placentae. The brain was extracted as follows; the scalped skull was 
opened carefully by fine scissors, starting laterally from the outer 
ear foramen and moving forwards. By using forceps, the roof of the 
skull bones was carefully removed in pieces. The brain was finally 
separated from the skull base after cutting all the cranial nerves. 
Parts of the liver and brain tissues of pregnant rats and fetuses of 
different groups were stored at-20 ˚C for further investigations.  
Alkaline comet assay 
DNA damage baseline level was estimated in Pregnant rats, and their 
fetuses in both brain and liver tissues of rats injected with two 
different doses of LEV using alkaline (pH>13) comet assay according 
to Tice et al. [17]. Preparation of slides, lysis, and electrophoresis, 
were conducted under red light in order to prevent additional DNA 
damage. Cells from 10 µl aliquot of homogenized brain or liver tissue 
in cold mincing solution (Hanks balanced Salt Solution (HBSS) 
Ca++and Mg++free with 20 mM EDTA, 10% Dimethyl sulphoxide 
(DMSO) was mixed with 75 µl of 0.5% low melting point agarose 
(Sigma) and was added to a fully frosted microscope slide pre-
coated with 1% of normal melting agarose. After solidification, slides 
were placed in a cold fresh lysing solution (2.5 M NaCl, 100 mM 
EDTA, 10 mM Tris, pH 10, to which 1% Triton X-100 and 10% DMSO 
were freshly added) for 24 h at 4 °C in the dark. Subsequently, the 
slides were incubated in freshly-made alkaline buffer (300 mM 
NaOH and 1 mM EDTA, pH>13) for 20 min. Electrophoresis was 
performed for 20 min at 300 mA and 25 V (0.90 V⁄cm), and then the 
alkali was neutralized with 0.4 m Tris (pH7.5), fixed in 100% cold 
ethanol and air dried. Finally, the DNA was stained with ethidium 
bromide (2 mg/ml). Using a fluorescence microscopy equipped with 
an integrated digital camera, images of 50 randomly selected cells 
were analyzed for: The Tail Moment (product of the proportion of 
the tail’s intensity and the displacement of the tail’s center of mass 
relative to the center of the head), tail Length (the extent of DNA 
damage away from the nucleus and expressed in µm, and % DNA in 
the tail were evaluated using Comet Assay IV software (Perceptive 
Instruments, Suffolk, UK) at 200x magnification.  
Qualitative DNA fragmentation assay 
DNA fragmentation was determined according to the standard 
protocol described by Sam brook [18]. Liver and brain Cells were 
suspended in 100 µl lysis buffer containing 10 mM Tris-HCl, pH 7.4, 
10 mM NaCl, 10 mM EDTA and 1% SDS, incubated with 50 μg/ml 
proteinase K at 56 °C overnight, and then centrifuged at 10,000 rpm 
for 30 min. Soluble DNA in the resulting supernatant was 
precipitated with ethanol at-20 °C, The DNA pellet was then rinsed 
with 70% ethanol and dissolved in sterile ddH2O. Fragmented DNA 
was detected by running 5 μg of genomic DNA on a 1.5% ethidium 
bromide treated agarose gel. The gel run at 80 Volt (Power Supply 
Biorad, Model 200/2.0), and visualized under UV transilluminator 
(Stratagene, USA)to visualize intranucleosomal DNA fragmentation 
(laddering), characteristic of apoptosis. 
Single strand conformation polymorphism (SSCP) analysis 
Isolation of genomic DNA 
Genomic DNA was prepared from rat liver and brain tissues using 
salting-out procedure performed as previously described [19]. 
Polymerase chain reaction (PCR) 
Primers for HRAS gene exons (2, 3) were designed to include codon 
12 (normal (N)=GGA), 13(N=GGC) in exon 2 and codon 61(N=CAA) 
in exon 3 as follow: exon 2 forward: 5’CAGGAGCT CCTGGATTGG, 
reverse: 5’AAAATGGTTCTGG ATCAG and exon 3 forward: 
5’GACTCCTACCGGAAA CAG, reverse: 5'GTGCGCATGTACTGGTC 
CCC3’. These hot spot codons are the most frequent position for a 
point mutation leading to an amino acid substitution in the encoded 
protein, and thus continuous transduction of inappropriate growth 
signal [20]. The size of the amplified region is 119 and 110 of exon 2 
and exon 3 respectively. 100 ng of extracted DNA, 10 pmol of both 
forward and reverse primers and 2 x master mixes were mixed. 
Samples were initially denatured at 94°c for 2 min followed by 35 
cycles of 1-minute denaturation at 94°c, 2 min annealing at 58°c and 
2 min elongation at 72 °c ended with a final extension step at 72°c 
for 7 min, and then cooling to 4°c. Cycling was carried out using 
Thermal Cycler (PTC-100™ thermal cycler, Watertown, MA, USA). 
The final products of PCR were separated and visualized by 
electrophoresis, through 2% ethidium bromide treated agarose gel 
using UV trans-illuminator (Stratagene, USA). 
SSCP analysis 
A mixture of 5 µl aliquot of the amplified PCR products, 5 μl of 
denaturing loading dye (95% formamide, 0.1% bromophenol blue, 
0.1% Xylene cyanol FF and 0.5 μl 15% Ficoll) and 5 µl of TE buffer 
was heat denatured at 95 °C for 5 min and then chilled on ice for 10 
min. The denatured PCR products was electrophoresed on a 20% 
polyacrylamide gel electrophoresis (acrylamide/bis-acrylamide = 
49:1, v/v) at 90 volt for 2 h. The gel was stained by shaking for 10 
min in 100 ml of 1× TBE with 10 μl ethidium bromide (10 mg/ml) to 
visualize the DNA bands. The stained gels were placed on a UV 
transilluminator (Stratagene, USA) and photographed using Medidoc 
gel documentation system (Herolab, Wiesloch, Germany).  
Direct sequencing  
Samples that showed different band pattern compared with their 
corresponding normal control, using SSCP analysis, were considered 
to harbor mutations. Their PCR products were electrophoresed on 
2% agarose gel, and purified using QIAquick® Gel Extraction Kit 
(QIAGEN, USA), according to the manufacturer’s recommendations. 
The samples were sequenced by the dideoxy chain termination 
method, using the original set of primers. DNA sequencing was 
performed on an ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems, USA), using ABI PRISM®BigDye™ Terminator v3.0 
Ready Reaction Cycle Sequencing Kit (Applied Biosystems, USA). 
Forward and reverse Sequences were compared against the 
corresponding rat gene sequence in NCBI database (Genbank 
accession number NM_001130441.1), for HRAS exon 2 (119 base 
pair (bp)) and exon 3(110bp), (132-249 bp, 278-387 bp on the 
corresponding mRNA respectively). 
Statistical analysis 
The effect of different parameters on the tail moment was tested 
using Univariate Analysis of Variance. Duncan’s test was used to 
evaluate the significant difference of tail moment between all 
groups. Regression analysis was also done to investigate the 
correlation between different LEV concentrations and tail moment. 
Chi-square () test was applied to clarify the effect of different 
doses of LEVon the studied gene mutations. In order to test the 
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significant differences of mutations between the experimental 
groups, Mann-Whitney test was applied. Statistics were carried out 
using the Statistical Package for the Social Sciences (SPSS) version 
20 package software. 
RESULTS 
Clinical signs of toxicity 
No mortality was observed in any of the treated groups. All female 
rats dosed with the control substances or dosed with LEV at 
concentrations of 300 or 600 mg/kg b.w, appeared normal 
throughout the experiment. Furthermore, LEV did not cause 
miscarriage in female rats. In addition, intragastric LEV exposure at 
the tested doses did not affect the gestation duration. 
Comet assay 
The statistical significant increase (p<0.001) in DNA migration from 
the nucleus (fig. 1), as assessed by tail moment (TM), indicated that the 
administration of LEV at 300 and 600 mg/kg b. w has induced DNA 
damage when compared with negative control group in the maternal 
and fetal liver and brain tissues. Simultaneously, hepatic cells showed 
a significant increase in DNA damage when compared with neural cells 
in both pregnant rats and their fetuses (p<0.001). Overall results 
showed a significant increase (p<0.001) in TM in pregnant rats 
compared to their fetuses in the tested tissues at both doses (table 1). 
Regression analysis indicated a strong positive correlation between 
tail moment and different LEV concentrations in all maternal and 
fetal tissues tested (fig. 2). 
The effect of different factors (doses, organs, cases) on TM, using 
Univariate ANOVA test, have caused a significant effect on the TM at 
p<0.001; except (cases, organs) and (doses, organs, cases) which 
showed an insignificant effect at p>0.05 (table 2). 
 
 
Fig. 1: Representative photo for DNA damage inductions by LEV 
doses (B) compared with undamaged DNA (A), (200 x)
 
Table 1: The effect of Levetiracetam (LEV) different concentrations on tail moment (TM) in the hepatic and neural cells of treated 
pregnant rats and their fetuses after daily injection from gestation days 5-18 
Doses 
of LEV 
Fetuses Pregnant rats (%)◄ (%)► 
Liver Brain (%)֎  Liver Brain (%)☼ 
0 mg/kg 0.0765±0.006A 0.0807±0.005A -5.5% 0.1600±0.016B 0.0774±0.002A +51.6% (+109.2%) (-4.1%) 
300 mg/kg 0.3018±0.022C 0.1056±0.006AB +65.0% 0.4593±0.017EF 0.3264±0.029D +28.9% (+52.2%) (+209.1%) 
% of change⊕ (+294.5%) (+30.9%)  (+187.1%) (+321.7%)    
600 mg/kg 0.5216±0.037EF 0.2475±0.003C +52.6% 0.7300±0.048G 0.4423±0.043DE +39.4% (+40.0%) (+78.7%) 
% of change⊕ (+581.8%) (+206.7%)  (+356.3%) (+471.5%)    
Data are represented as a mean of five rats±standard error of the mean (SEM), Mean values marked with the same letter are similar (insignificant, 
P>0.05), ⊕: Percentage of changes in comparison with the corresponding control, ֎ , ☼: Percentage of changes of the liver TM in comparison with 
the corresponding TM in neural cells of the fetuses and pregnant rats respectively, ◄, ►: Percentage of changes of the mother hepatic and brain TM 
in comparison with those of the corresponding fetuses, respectively. 
 
Table 2: The effect of different doses of LEV (0,300,600 mg/kg b. w), organs (liver, brain), cases (fetuses, pregnant rats) and their 
interactions on the tail moment in the treated albino rats using Multivariate ANOVA test 
Source Type III Sum of squares Df Mean square F Sig. 
Corrected Model 1.463a 11 .133 71.944 p<0.001 
Intercept 3.114 1 3.114 1684.468 p<0.001 
Doses .897 2 .449 242.764 p<0.001 
Organs .235 1 .235 127.013 p<0.001 
Case .186 1 .186 100.421 p<0.001 
Doses * Organs .088 2 .044 23.723 p<0.001 
Doses * case .048 2 .024 13.110 p<0.001 
Organs * case .000 1 .000 .186 p>0.05 
Doses * Organs * case .008 2 .004 2.284 p>0.05 
Error .044 24 .002   
Total 4.621 36    
Corrected Total 1.507 35    
P>0.05: insignificant effect; P<0.001: significant effect at α= 0.01. 
 
DNA fragmentation 
DNA obtained from maternal tissues treated with different doses 
was detected as dense smears at size 500 and 100 bp compared to 
intact genomic DNA in the negative group (fig.3). However, low level 
of DNA degradation was detected as less dense smears in the fetal 
tissues at (100 bp). The degree of DNA fragmentation at dose 600 
mg/kg was higher than that at 300 mg/kg dose in both maternal and 
tested fetal tissues. 
SSCP analysis 
PCR products of exon 2 and 3 of HRAS gene measuring 119bp, 110bp 
respectively (fig.4), were analyzed by SSCP to identify DNA 
harboring mutation, all of which were identified either as an extra 
lower band in exon 2 or as band shifts in exon 3 (fig. 5A and 6A). 
Liver and brain tissues of five pregnant rats and their thirty fetuses 
were examined for each dose and exons. In the treated maternal 
brain tissue, SSCP analysis of exon 3 showed no mutation, while 
exon 2 revealed two mutations out of five (40%) at dose300 mg/kg 
b. wand three mutations out of five (60%) at dose 600 mg/kg b.w. 
No abnormal SSCP pattern was detected in the treated maternal 
liver tissue at the doses tested for both exons. In fetuses, five 
mutations out of thirty (16.6%) were observed for each exon, 
concerning exon 2, mutations observed only in liver tissue at dose 
300 mg/kg b. w, while those in exon 3 appeared only in brain tissue 
at dose 600 mg/kg b.w. 
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Fig. 2: Regression lines and correlation coefficients for a tail moment affected by daily injection of LEV different concentrations in hepatic 
(A) and neural cells (B) of treated pregnant rats and their fetuses from 5th-18th days of gestation. Results are expressed as mean 
 
 
Fig. 3: DNA fragmentation using agarose gel electrophoresis of 
DNA isolated from liver and brain of pregnant rats (A) and their 
fetuses (B) rat, Compared with DNA marker (M) and their 
control (C) at the tested doses (300 or 600 mg/kg b. w) 
Fragmented DNA was indicated by arrows 
 
 
Fig. 4: PCR products of HRAS gene exons 2 and 3 electrophoresed on 
1.5% agarose, stained with ethidium bromide. M: the ladder 
marker, lanes (1, 2, 3): PCR products of HRAS exon 2 at 119 bp, 
lanes (10, 11, 12): PCR products of HRA Sexon 3 at 110 bp 
 
Sequence analysis 
PCR products of 8 treated samples that showed abnormal patterns 
in SSCP than control were randomly selected. Two PCR products of 
exon 3 from fetal liver tissue treated with 600 mg/kg b. wand six 
samples of exon 2, (two treated samples of maternal brain tissue 
for each tested doses and two treated samples of fetal liver tissues 
at dose 300 mg/kg b. w) were chosen. In addition, two treated 
samples that showed no difference in SSCP pattern compared to 
their control were sequenced as well for more conformation and 
their sequence alignment showed no difference from that of their 
controls or Genbank data sequence. In exon 2, same point 
mutations were observed in the six tested samples out of the 
coding region, at nucleotide (nt) positions 24, 155 (C/G) and 35, 
166 (G/T).  
Frameshift mutation was found due to insertion font (C) at position 
43, 174 (second base of codon 3) (fig. 5C). Synonymous point 
mutations were detected in exon 3 at nucleotide positions 21, 298 
(A/G, Valine to Valine) and 39,316 (G/A, Leucine to Leucine) and 43, 
320(T/C, Threonine to Threonine) in the third base of codon 44, in 
the third base of codon 50, and in the first base of codon 52 
respectively (fig. 6C), no mutation has been observed in any hot spot 
codons of exons 2 or 3.  
According to results of Chi-square test, different injected doses did 
not induce any statistical significant alterations (p>0.05) in band 
pattern in both exons 2 and 3 in the maternal organs tested when 
compared with the negative controls values. On the other hand, 
statistical significant alterations (P<0.05) in band pattern in exon 2 
and exon 3 in the liver and brain fetal tissues respectively, have been 
observed (table 3). 
DISCUSSION 
Although, lots of drugs were discovered using animal models, a big 
portion of patients still remain resistant to the available antiepileptic 
drugs [21]. The growing importance of LEV in medical practice 
today, as an AED of low incidence of side effects and proven efficacy, 
and considering that AEDs in general are transplacental agents [22], 
beside the absence of enough information about its drug metabolism 
interaction, have implied the urge to investigate its potential 
genotoxic effects in maternal and fetal tissues. In the present study, 
the experimental animals are provided with the therapeutic and the 
higher doses of the test compound, to reach the plasma 
concentrations that are in accordance with those expected under 
clinical conditions. 
The results of the comet assay have evidenced that both tested 
concentrations have induced strand breaks as indicated by the 
significant elevations in a tail moment in a concentration-dependent 
manner. The appearance of the smeared pattern of genomic DNA 
fragments in the range of 20–300 kb, is an early sign of cellular 
apoptosis. That profits the generation of low molecular weight 
oligonucleosomal fragments [23], further evidenced DNA damage 
inductions and fragmentation by the two tested LEV concentrations. 
The significant increase of tail moment in fetal hepatic and neural 
cells is an indication of the transplacental genotoxic effects of this 
drug. Although the exact mechanism for LEV–induced DNA damage 
in neural cells is not known, it has been postulated as being caused 
by apoptosis, which is regulated by growth factors and cytokines as 
well as by neurotransmitters and is accomplished by a number of 
intracellular proteins [5]. As studies speculate that LEV may involve 
induction of GABA and glycine-mediated inhibition, and/or synaptic 
protein binding which alters neurotransmitter release [4], 
interference with these processes by any compound including LEV 
may trigger apoptotic death of neurons and cause DNA damage [6]. 
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Fig. 5: (A): Representative 10% polyacrylamide gel showing a PCR-SSCP pattern for HRAS gene exon 2 (119bp) with the extra lower band 
(lane 2) relative to control (lane 1). (B): Sequence graph of control of region flanking (15-49bp) showing the normal nucleotide (nt) using 
a forward primer. (C): Sequence graph of region flanking mutations (15-50bp) showing substitution of nt C/G and G/T and at positions 24, 
155 and 35,166 respectively, and insertion of nt C at position 43, 174 using forward primer.(D): Amino acid translation and alignment 
between mutant coding sequence (starting from 36, 167bp till the end of exon 2) and the control showing frame shift starts at codon three 
indicated by arrow 
 
 
Fig. 6: (A) Representative 10% polyacrylamide gel showing a PCR-SSCP pattern for HRAS gene exon 3 (110bp) with band shift (lane 2) 
relative to control (lane 1). (B): Sequence graph of control of region flanking (11-51) showing the normal nucleotide (nt) using a forward 
primer. (C): Sequence graph of region flanking mutation (11-52) showing substitution of nt A/G, G/A and T/C at positions (21,298); 
(39,316) and (43, 320) respectively using forward primer 
 
Table 3: Chi-square to clarify the effect of the different doses of LEV on the HRAS gene alterations observed in exon 2 and exon 3 in the 
liver and brain of treated pregnant rats and their fetuses after daily injection from 5th-18th days of gestation 
 Fetal Liver Fetal Brain Maternal Liver Maternal brain 
 EX 2 EX 3 EX 2 EX 3 EX 2 EX 3 EX 2 EX 3 
Chi-Square 10.471 0.000 0.000 10.471 0.000 0.000 3.920 0.000 
Df 2 2 2 2 2 2 2 2 
P-value 0.005 1.000 1.000 0.005 1.000 1.000 0.141 1.000 
P>0.05: insignificant effect; P<0.05: significant effect at α= 0.05. 
 
The present results are concurrent with many researchers [24-26], 
that studied the neurotoxic effects of AEDs in infant rodents. They 
found that most AEDs cause apoptotic neurodegeneration in the 
developing rat brain, at doses and plasma concentrations relevant 
for anticonvulsant treatment [24-26]. Kim et al.[27] study on 
postnatal 8 d-old rats, in contrary to our findings, demonstrated that 
LEV alone did not cause cell death in the rat brain when given in 
therapeutic doses, and did not act together with other drugs as well.  
The present study has shown no significant increase in the tail 
moment between treated fetuses at a dose (300 mg/kg) and the 
reference group in brain tissues (% of change=+30.9%). This is may 
be contributed to MDRPs (multidrug resistance proteins) that 
transport AEDs toward the blood compartment, confined to the 
apical membrane of brain capillary endothelial cells, thereby 
retained them within the brain, and limiting their penetration [28]. 
Nevertheless, this was not the case in maternal tissues, as they 
revealed a significant increase in the tail moment at such does with 
the referent group (p<0.05) (% of change=+321.7%). Consequently, 
it was concluded that distribution and bioaccumulation of AEDs, are 
different in fetus and mother, which revealed the different 
susceptibility between them.  
Concerning hepatocytes injury, several studies confirming that LEV 
use was unavoidably linked to hepatic failure [29, 7, 8]. Based on the 
biopsy, Tan et al., [7] reported that LEV had caused hepatocyte death 
without producing any structural changes to the liver. In addition, 
Huda and Muna [30]showed that the hepatocellular lesions, 
congestion of central veins, focal necrosis, dilatation and congestion 
of portal veins, were noticed in the liver sections of rats, treated with 
a high dose of LEV (70 mg/kg body weight). All previously 
mentioned studies support the present findings of hepatocyte injury, 
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assessed by a significant increase of DNA damage, in maternal and 
fetal hepatic cells. That could be rationalized by either decreased 
free radical neutralization and/or an increased production of free 
radicals, which may explain DNA damage in the liver. This 
hypothesis was further reinforced by Skopp et al. [9] and Ozden’s 
[31] reports. The oxidative metabolism and the formation of reactive 
intermediates or metabolites could be another elucidation, which 
has been proposed as possible mechanisms of the teratogenicity for 
several clinically important AEDs, including CBZ and PHT [32]. 
Reactive metabolites from AED can, in some cases, cause direct 
cytotoxicity and liver cell necrosis [33]. Cytotoxic effect of LEV was 
distinguished using acid phosphatase assay (AP), only at higher 
concentrations. AP is a functional marker of the lysosomal 
compartment, and the lysosomal enzymes are known to recruit cell 
death [34]. All of which can cause DNA damage in liver tissues. 
However, the mechanism of LEV-induced liver stays puzzling. 
Genetic variations, either resulting from spontaneous mutations or 
as a cause of xenobiotic exposure, may disturb the normal 
patterning and lead to a wide variety of skeletal alterations [35]. 
Limited studies on LEV, have reported that it's genotoxic and 
teratogenic effect risk are low in case it is used in pregnancy [36, 
37]. On the other hand, fetal skeletal anomalies are seen in several 
studies at high doses of LEV [38, 39]. Moreover, exposure of rat pups 
to LEV doses ≥350 mg/kg/day, throughout their development, had 
increased the incidence of minor skeletal abnormalities and growth 
retardation, whereas doses of 1,800 mg/kg/day also led to increased 
embryonic mortality [36]. These reports reflect the possible 
mutagenic potential of LEV. 
As no current publications regarding LEV mutagenicity exists, this 
study was carried out to reveal the potential mutagenic effect of this 
drug. Different SSCP patterns and mutations in exon 2 and 3 of HRAS 
gene were shown. According to chi-square test, maternal brain 
tissues exhibit insignificant incidence of mutation in exon 2, at both 
tested doses compared to negative control. This is may be attributed 
to the short time of administration. On the other hand, the significant 
mutation induction (P<0.05) that were detected in fetal liver and 
brain tissues, indicated higher susceptibility of fetuses. Mutations in 
exon 3 detected in brain tissues of fetuses at dose 600 mg/kg could 
be explained by the water solubility of LEV, and the crossing of the 
blood-brain barrier [40]. Taking into consideration that 66% of the 
administered LEV dose is excreted unchanged in the urine, with an 
additional 24% of the administered dose excreted as the 
corresponding inactive acid metabolite 2-pyrrolidinone-N-butyric 
acid (PBA) in human [41]. Besides the two high-PBA dosages (600 
and 1,200 mg/kg/day), specifically increased the incidence of 
hypoplastic phalanges as reported by Nina et al.[40]. Thus, the 
mutagenic impact of LEV may be attributed either to its metabolite 
PBA effects, although at present no distributed data exists with 
respect to its reproductive safety, or to the induction of oxidative 
stress as reported by Ozden [31]. Redundant free radicals have been 
shown to interact with biomolecules including proteins, enzymes, 
membrane lipids and DNA which could be oxidized, destructured 
and ultimately dysfunctional [42]. Reactive oxygen species (ROS) 
can oxidize double bonds on fatty acid tails of membrane 
phospholipids, peroxidized fatty acids can trigger reactions that 
generate other free radicals, leading to more cell membrane and 
DNA damage, including DNA strand breaks, cross-linking, and 
adducts of the bases or sugars, single base and sugar phosphate 
damage [43]. Previously mentioned studies confirmed results of the 
present study and rationalized the different patterns of SSCP and 
types of mutations in HRAS gene exons 2, 3. 
The reason behind exhibiting 5% mutant infants after exposure to 
LEV while the remaining 95% were unaffected are not clearly 
understood. However, there is an increasing evidence that the 
placenta has the ability to protect the fetus from drugs and 
xenobiotics in the maternal circulation [44]. Therefore, there may be 
a relationship between the protective function of the placenta, and 
the susceptibility to birth imperfections in some fetuses. 
Our findings demonstrate that LEV-induced geno toxicity and 
mutagenicity in developing rat embryos at the therapeutic dose, and 
caused a significant increase in the tail moment, and DNA 
fragmentation at dose exceeded the therapeutic one. That may 
provide unsafely use for the pregnant, epileptic population after 
chronic administration. Future studies should address the 
underlying molecular mechanisms and implications of the observed 
prenatal effects of Levetiracetam. 
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